Long-term effects: Galectin-1 and specific immunotherapy for allergic responses in the intestine.
Allergy
; 73(1): 106-114, 2018 Jan.
Article
em En
| MEDLINE
| ID: mdl-28718965
ABSTRACT
BACKGROUND AND AIMS:
Mast cell activation interferes with the effects of allergen-specific immunotherapy (SIT). Galectin-1 (Gal-1) is capable of regulating immune cells' functions. This study tests the hypothesis that administration of Gal-1 promotes and prolongs the efficacy of SIT via suppressing mast cell activation.METHODS:
An intestinal allergy mouse model was developed. The coadministration of SIT and Gal-1 on suppression of the allergic responses, prevention of mast cell activation, and generation of antigen-specific regulatory T cells (Treg) in the intestine was observed in sensitized mice.RESULTS:
The coadministration of Gal-1 and SIT markedly suppressed the allergic responses in the mouse intestine vs the use of either SIT alone or Gal-1 alone. The Gal-1 binds to the IgE/FcÉRI complexes on the surface of mast cells to prevent mast cell activation during SIT. Gal-1 promoted the SIT-generated allergen-specific Tregs in the intestine of sensitized mice. Coadministration of Gal-1 and SIT significantly enhanced the efficacy of immunotherapy in suppressing allergic responses in the intestine, which lasted for at least for 12 months.CONCLUSIONS:
Long-term effects of specific immunotherapy on intestinal allergy can be achieved with Gal-1/SIT therapy by inhibiting mast cell activation and facilitating Treg development.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Alérgenos
/
Galectina 1
/
Hipersensibilidade
/
Imunoterapia
/
Intestinos
Limite:
Humans
Idioma:
En
Ano de publicação:
2018
Tipo de documento:
Article